GSK Investigational Site

Ciudad Autonoma Buenos Aires, Buenos Aires C1430EGF

0 studies enrolling now · 6 studies all time

What they study most

Arthritis, Rheumatoid, Lupus Nephritis, Meningitis, Meningococcal, Systemic Lupus Erythematosus

Studies at this site

• Belimumab Assessment of Safety in SLE — Completed
• Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine — Completed
• Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) — Stopped early
• Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) — Stopped early
• Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors — Completed
• Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis — Completed